Description
A mycotoxin with antimicrobial, cytotoxic, and toxic properties; inhibits the growth of B. subtilis, M. luteus, C. perfringens, B. fragilis, MRSA, C. albicans, S. cerevisiae, M. racemosus, A. niger, and P. chrysogenum (MICs = 0.39-25 µg/ml); inhibits the production of polyprenyl alcohols by S. aureus UPP synthase, E. coli OPP synthase, and S. cerevisiae DedoIPP synthase in vitro (IC50s = 3.1, 21, and 71 µM, respectively); has cytotoxic effects against human Jurkat T (IC50 = 4.92 µM), CLL (LC50 = 0.7-3.5 nM), and bone marrow-derived HS-5 stromal cells; toxic to rats and mice when administered intraperitoneally (LD50s = 80 and 90 mg/kg, respectively) and to rats when administered via gastric intubation (LD50 = 122.4 mg/kg), but not to rats or mice when administered orally or through subcutaneous injection
Formal name: (1R,7’aR,11’aR,12’R)-rel-(-)-7′,7’a,8′,11′,11’a,12′-hexahydro-5′,6′,7’a,10′,11’a,12′-hexahydroxy-3′-methoxy-2,6,6-trimethyl-7′,8′-dioxo-spiro[2-cyclohexene-1,2′(1’H)-cyclopenta[de]naphthacene]-9′-carboxamide
Synonyms: NSC 159628
Molecular weight: 565.6
CAS: 39277-41-3
Purity: ≥95%
Formulation: A solid
Product Type|Biochemicals|Antibiotics||Product Type|Biochemicals|Antifungals||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Product Type|Biochemicals|Toxins|Mycotoxins||Research Area|Cancer|Cell Death||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Bacterial Diseases|Food-borne Illnesses||Research Area|Infectious Disease|Bacterial Diseases|MRSA||Research Area|Infectious Disease|Bacterial Diseases|Pneumonia||Research Area|Infectious Disease|Fungal Diseases|Aspergillosis||Research Area|Infectious Disease|Fungal Diseases|Candidiasis||Research Area|Toxicology|Cell Health & Viability
